treatment with Vhcl or 50 nmol/kg of either GLP-1RA, Tesaglitazar, GLP-1RA + Tesglitazar or GLP-1RA/Tesaglitazar
This compound is supplied in lyophilized (freeze-dried) powder form to enhance stability for controlled laboratory research applications
doi: 10.1111/dom.13420
Their multifaceted benefits, including significant improvements in glycemic control and weight reduction, together with cardiovascular and renal protection, have led to their widespread use across various clinical settings [8,9,10]
Injection site reactions redness, swelling, itching are consistent with class effects seen with authorised GLP-1-based agents such as semaglutide and tirzepatide
The most common is 5mg/mL, available in 0.5 mL vials (2.5 mg total), 1 mL vials (5 mg total), and 2 mL vials (10 mg total)